PDL BioPharma, Inc. (NASDAQ:PDLI)

CAPS Rating: 4 out of 5

A biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for severe or life-threatening illnesses.

Recs

0
Player Avatar MichaelHamilton (92.69) Submitted: 5/19/2011 6:19:26 PM : Underperform Start Price: $5.90 PDLI Score: -11.51

garbage

Featured Broker Partners


Advertisement